Replies to post #16430 on BioCurex, Inc.(fka BOCX)

[opportunityknocking]

The results for ovarian cancer using Serum-RECAF show a sensitivity of 90% with 95% specificity. The current marker of choice for ovarian cancer is CA-125 and it has a sensitivity of only 77% compared with the 90% found with Serum-RECAF.
It makes no sense that you insist recaf has no value. I beg to differ and clearly see it at face value for what is worth. Everyone knows you have one mission. Destroy Biocurex. Now debate that!
You are wrong and are only a lay person with a vendetta. This has been apparent for quite some time but I expect a great ISOBM in about one week, so enjoy your last jabs.